Idarubicin is a compound of defined chemical structure and pharmaceutical significance whose toxicological characterisation supports health-based exposure limit derivation for pharmaceutical manufacturing occupational safety and cross-contamination control. The relationship between molecular structure and biological potency—assessed through structure-activity relationship analysis and experimental pharmacological and toxicological data—determines the OEB classification and the engineering containment requirements governing manufacturing operations involving Idarubicin.
Study duration uncertainty factor F3 in PDE derivation for Idarubicin compensates for the data gap between the duration of available toxicology studies and the chronic lifetime pharmaceutical exposure scenario. F3 equals 1 when a ≥12-month rodent study or 9-month non-rodent study forms the basis; F3 is set at 2 for 6-month studies, 5 for 13-week sub-chronic studies, and up to 10 when only 28-day or shorter studies are a
